OKYO Pharma (OKYO) Cash from Operations (2024 - 2026)
OKYO Pharma's (OKYO) quarterly Cash from Operations came in at -$5.9 million in Q1 2026, down 2000.94% quarter-over-quarter from -$282535.0 in Q4 2025.
Powered by 
Analysis
OKYO Pharma (OKYO) Cash from Operations (2024 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Cash from Operations for 3 consecutive years, with -$5.9 million the latest figure, recorded in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 4.00 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.57 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.13 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 813.00 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -526.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 448.90 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -88.83 Mn |
| 10 | OKYO Pharma | 1.06 Bn | 1.06 Bn | - | -5.94 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -5.94 Mn |
| Dec 31, 2025 | -282,535.00 |
| Dec 31, 2024 | -9.49 Mn |